Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535989 | 0.79 | MAPK1 (0.34) | MAPK1HSD17B10TSHRNPC1RAB9A | |
| SCHEMBL12431439 | 0.79 | TSHR (0.38) | MAPK1HSD17B10TSHRNPC1RAB9A | |
| SCHEMBL1535991 | 0.79 | MAPK1 (0.34) | MAPK1HSD17B10TSHRNPC1RAB9A | |
| SCHEMBL11784062 | 0.79 | ALDH1A1 (0.40) | TSHRALDH1A1 | |
| SCHEMBL25713185 | 0.77 | MAPK1 (0.33) | MAPK1HSD17B10TSHRNPC1RAB9A | |
| SCHEMBL13433278 | 0.77 | — | — | |
| SCHEMBL9005349 | 0.77 | MAPK1 (0.33) | MAPK1HSD17B10TSHRNPC1RAB9A | |
| SCHEMBL16850495 | 0.77 | MAPK1 (0.33) | MAPK1HSD17B10TSHRNPC1RAB9A | |
| SCHEMBL16337476 | 0.75 | TSHR (0.36) | MAPK1HSD17B10TSHRNPC1RAB9A | |
| SCHEMBL13725736 | 0.73 | TSHR (0.38) | MAPK1HSD17B10TSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| CN-111822236-B | Adhesive coating device and manufacturing method of planar capacitor | 深圳市峰泳科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-111822236-A | Adhesive coating device and manufacturing method of planar capacitor | 深圳市峰泳科技有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1900715-A1 | FLUORENE DERIVATIVE, TRANSITION METAL COMPOUND, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER | Mitsui Chemicals, Inc. (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-20070031339-A1 | Contrast agents | GE HEALTHCARE AS (NO) | 2007-02-08 | — | — | US | disclosed |
| US-4863642-A | CARBOXYLATION, ACID ACTALYSTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0070463-B1 | PROCESS FOR THE PREPARATION OF ACID HALIDES | BAYER AG (DE) | 1985-01-09 | — | — | EP | disclosed |
| EP-0073301-B1 | PROCESS FOR THE PREPARATION OF ALPHA, BETA AND BETA, GAMMA UNSATURATED KETONES | FIRMENICH SA (CH) | 1984-11-21 | — | — | EP | disclosed |
| US-4453011-A | BASIFICATION OF A DIALLYL CARBINOL | FIRMENICH SA (CH) | 1984-06-05 | — | — | US | disclosed |
| EP-0073301-A1 | Process for the preparation of alpha, beta and beta, gamma unsaturated ketones | FIRMENICH SA (CH) | 1983-03-09 | — | — | EP | disclosed |
| EP-0070463-A1 | Process for the preparation of acid halides | BAYER AG (DE) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | MAPK1 235/4885HSD17B10 2104/4885TSHR 2843/4885 |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | MAPK1 1129/4885HSD17B10 3787/4885TSHR 4752/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | MAPK1 2346/4885HSD17B10 622/4885TSHR 4635/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | MAPK1 1129/4885HSD17B10 3787/4885TSHR 4752/4885 |
| US-20070031339-A1 | Contrast agents | TSG101, PRTN3, KATNAL2 | MAPK1 1747/4885HSD17B10 4845/4885TSHR 1407/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPK1 4884/4885HSD17B10 223/4885TSHR 2837/4885 |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MAPK1 316/4885HSD17B10 4594/4885TSHR 2616/4885 |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | MAPK1 279/4885HSD17B10 4692/4885TSHR 2965/4885 |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | MAPK1 1129/4885HSD17B10 3787/4885TSHR 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.